As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
7 Analysts have issued a Mustang Bio, Inc. forecast:
7 Analysts have issued a Mustang Bio, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -11 -11 |
71%
71%
|
EBIT (Operating Income) EBIT | -11 -11 |
70%
70%
|
Net Profit | -11 -11 |
73%
73%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
Head office | United States |
CEO | Manuel Litchman |
Employees | 6 |
Founded | 2015 |
Website | www.mustangbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.